Prognostic effect of weight loss prior tochemotherapy in cancer patients

William D. Dewys; Colin Begg; Philip T. Lavin; Pierre R. Band; John M. Bennett; Joseph R. Bertino; Martin H. Cohen; Harold O. Douglass; Paul F. Engstrom; Ediz Z. Ezdinli; John Horton; Gerhard J. Johnson; Charles G. Moertel; Martin M. Oken; Charles Perlia; Charles Rosenbaum; Murray N. Silverstein; Roland T. Skeel; Robert W. Sponzo; Douglass C. Tormey

doi:10.1016/S0149-2918(05)80001-3

Prognostic effect of weight loss prior tochemotherapy in cancer patients

William D. Dewys, Colin Begg, Philip T. Lavin, Pierre R. Band, John M. Bennett, Joseph R. Bertino, Martin H. Cohen, Harold O. Douglass, Paul F. Engstrom, Ediz Z. Ezdinli, John Horton, Gerhard J. Johnson, Charles G. Moertel, Martin M. Oken, Charles Perlia, Charles Rosenbaum, Murray N. Silverstein, Roland T. Skeel, Robert W. Sponzo, Douglass C. Tormey

Research output: Contribution to journal › Article › peer-review

726 Scopus citations

Abstract

The prognostic effect of weight loss prior to chemotherapy was analyzedusing data from 3,047 patients enrolled in 12 chemotherapy protocols of the Eastern Cooperative Oncology Group. The frequency of weight loss ranged from 31 percent for favorable non-Hodgkin's lymphoma to 87 percent in gastric cancer. Median survival was significantly shorter in nine protocols for the patients with weight loss compared to the patients with no weight loss. Chemotherapy response rates were lower in the patients with weight loss, but only in patients with breast cancer was this difference significant. Decreasing weight was correlated with decreasing performance status except for patients with pancreatic and gastric cancer. Within performance status categories, weight loss was associated with decreased median survival. The frequency of weight loss increased with increasing number of anatomic sites involved with metastases, but within categories of anatomic involvement, weight loss was associated with decreased median survival. These observations emphasize the prognostic effect of weight loss, especially in patients with a favorable performance status or a limited anatomic involvement with tumor.

Original language	English (US)
Pages (from-to)	491-497
Number of pages	7
Journal	The American Journal of Medicine
Volume	69
Issue number	4
DOIs	https://doi.org/10.1016/S0149-2918(05)80001-3
State	Published - Oct 1980
Externally published	Yes

Bibliographical note

Funding Information:
WILLIAM D. DEWYS, M.D. COLIN BEGG, Ph.D. PHILIP T. LAVIN, Ph.D. PIERRE R. BAND, M.D. JOHN M. BENNETT, M.D. JOSEPH R. BERTINO, M.D. MARTIN H. COHEN, M.D. HAROLD O. DOUGLASS, Jr., M.D. PAUL F. ENGSTROM, M.D. EDIZ-Z. EZDINLI, M.D. JOHN HORTON, M.D. GERHARD J. JOHNSON, M.D. CHARLES G. MOERTEL, M.D. MARTIN M. OKEN, M.D. CHARLES PERLIA, M.D. CHARLES ROSENBAUM, M.D. MURRAY N. SILVERSTEIN, M.D. ROLAND T. SKEEL, M.D. .:ROBERT W. SPONZO, M.D. DOUGLASS C. TORMEY, M.D. Eastern Cooperative Oneology Group* * The Eastern Cooperative Oncol0gy Group operations office is supported by Grant CA 21115 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services. Institutional affiliations of the participants of this study, which was conducted by the Eastern Co-operative Oncology Group (Paul P. Carbone, chairman), are listed at the end of the article. This study was supported by Public Health Service grants from the National Cancer Institute, National Institutes of Health, and the Department of Health and Human Services. Requests for reprints should be addressed to Dr. William D. DeWys, National Cancer Institute, Landow Building, Room 8C17, Bethesda, Maryland 20205. Manuscript accepted May 5, 1980.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/S0149-2918(05)80001-3

Find It

Find It at U of M Libraries

Cite this

Dewys, W. D., Begg, C., Lavin, P. T., Band, P. R., Bennett, J. M., Bertino, J. R., Cohen, M. H., Douglass, H. O., Engstrom, P. F., Ezdinli, E. Z., Horton, J., Johnson, G. J., Moertel, C. G., Oken, M. M., Perlia, C., Rosenbaum, C., Silverstein, M. N., Skeel, R. T., Sponzo, R. W., & Tormey, D. C. (1980). Prognostic effect of weight loss prior tochemotherapy in cancer patients. The American Journal of Medicine, 69(4), 491-497. https://doi.org/10.1016/S0149-2918(05)80001-3

Dewys, WD, Begg, C, Lavin, PT, Band, PR, Bennett, JM, Bertino, JR, Cohen, MH, Douglass, HO, Engstrom, PF, Ezdinli, EZ, Horton, J, Johnson, GJ, Moertel, CG, Oken, MM, Perlia, C, Rosenbaum, C, Silverstein, MN, Skeel, RT, Sponzo, RW & Tormey, DC 1980, 'Prognostic effect of weight loss prior tochemotherapy in cancer patients', The American Journal of Medicine, vol. 69, no. 4, pp. 491-497. https://doi.org/10.1016/S0149-2918(05)80001-3

@article{81b4fce954354435b58f4b294ca04281,

title = "Prognostic effect of weight loss prior tochemotherapy in cancer patients",

abstract = "The prognostic effect of weight loss prior to chemotherapy was analyzedusing data from 3,047 patients enrolled in 12 chemotherapy protocols of the Eastern Cooperative Oncology Group. The frequency of weight loss ranged from 31 percent for favorable non-Hodgkin's lymphoma to 87 percent in gastric cancer. Median survival was significantly shorter in nine protocols for the patients with weight loss compared to the patients with no weight loss. Chemotherapy response rates were lower in the patients with weight loss, but only in patients with breast cancer was this difference significant. Decreasing weight was correlated with decreasing performance status except for patients with pancreatic and gastric cancer. Within performance status categories, weight loss was associated with decreased median survival. The frequency of weight loss increased with increasing number of anatomic sites involved with metastases, but within categories of anatomic involvement, weight loss was associated with decreased median survival. These observations emphasize the prognostic effect of weight loss, especially in patients with a favorable performance status or a limited anatomic involvement with tumor.",

author = "Dewys, {William D.} and Colin Begg and Lavin, {Philip T.} and Band, {Pierre R.} and Bennett, {John M.} and Bertino, {Joseph R.} and Cohen, {Martin H.} and Douglass, {Harold O.} and Engstrom, {Paul F.} and Ezdinli, {Ediz Z.} and John Horton and Johnson, {Gerhard J.} and Moertel, {Charles G.} and Oken, {Martin M.} and Charles Perlia and Charles Rosenbaum and Silverstein, {Murray N.} and Skeel, {Roland T.} and Sponzo, {Robert W.} and Tormey, {Douglass C.}",

note = "Funding Information: WILLIAM D. DEWYS, M.D. COLIN BEGG, Ph.D. PHILIP T. LAVIN, Ph.D. PIERRE R. BAND, M.D. JOHN M. BENNETT, M.D. JOSEPH R. BERTINO, M.D. MARTIN H. COHEN, M.D. HAROLD O. DOUGLASS, Jr., M.D. PAUL F. ENGSTROM, M.D. EDIZ-Z. EZDINLI, M.D. JOHN HORTON, M.D. GERHARD J. JOHNSON, M.D. CHARLES G. MOERTEL, M.D. MARTIN M. OKEN, M.D. CHARLES PERLIA, M.D. CHARLES ROSENBAUM, M.D. MURRAY N. SILVERSTEIN, M.D. ROLAND T. SKEEL, M.D. .:ROBERT W. SPONZO, M.D. DOUGLASS C. TORMEY, M.D. Eastern Cooperative Oneology Group* * The Eastern Cooperative Oncol0gy Group operations office is supported by Grant CA 21115 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services. Institutional affiliations of the participants of this study, which was conducted by the Eastern Co-operative Oncology Group (Paul P. Carbone, chairman), are listed at the end of the article. This study was supported by Public Health Service grants from the National Cancer Institute, National Institutes of Health, and the Department of Health and Human Services. Requests for reprints should be addressed to Dr. William D. DeWys, National Cancer Institute, Landow Building, Room 8C17, Bethesda, Maryland 20205. Manuscript accepted May 5, 1980.",

year = "1980",

month = oct,

doi = "10.1016/S0149-2918(05)80001-3",

language = "English (US)",

volume = "69",

pages = "491--497",

journal = "American Journal of Medicine",

issn = "0002-9343",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Prognostic effect of weight loss prior tochemotherapy in cancer patients

AU - Dewys, William D.

AU - Begg, Colin

AU - Lavin, Philip T.

AU - Band, Pierre R.

AU - Bennett, John M.

AU - Bertino, Joseph R.

AU - Cohen, Martin H.

AU - Douglass, Harold O.

AU - Engstrom, Paul F.

AU - Ezdinli, Ediz Z.

AU - Horton, John

AU - Johnson, Gerhard J.

AU - Moertel, Charles G.

AU - Oken, Martin M.

AU - Perlia, Charles

AU - Rosenbaum, Charles

AU - Silverstein, Murray N.

AU - Skeel, Roland T.

AU - Sponzo, Robert W.

AU - Tormey, Douglass C.

N1 - Funding Information: WILLIAM D. DEWYS, M.D. COLIN BEGG, Ph.D. PHILIP T. LAVIN, Ph.D. PIERRE R. BAND, M.D. JOHN M. BENNETT, M.D. JOSEPH R. BERTINO, M.D. MARTIN H. COHEN, M.D. HAROLD O. DOUGLASS, Jr., M.D. PAUL F. ENGSTROM, M.D. EDIZ-Z. EZDINLI, M.D. JOHN HORTON, M.D. GERHARD J. JOHNSON, M.D. CHARLES G. MOERTEL, M.D. MARTIN M. OKEN, M.D. CHARLES PERLIA, M.D. CHARLES ROSENBAUM, M.D. MURRAY N. SILVERSTEIN, M.D. ROLAND T. SKEEL, M.D. .:ROBERT W. SPONZO, M.D. DOUGLASS C. TORMEY, M.D. Eastern Cooperative Oneology Group* * The Eastern Cooperative Oncol0gy Group operations office is supported by Grant CA 21115 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services. Institutional affiliations of the participants of this study, which was conducted by the Eastern Co-operative Oncology Group (Paul P. Carbone, chairman), are listed at the end of the article. This study was supported by Public Health Service grants from the National Cancer Institute, National Institutes of Health, and the Department of Health and Human Services. Requests for reprints should be addressed to Dr. William D. DeWys, National Cancer Institute, Landow Building, Room 8C17, Bethesda, Maryland 20205. Manuscript accepted May 5, 1980.

PY - 1980/10

Y1 - 1980/10

N2 - The prognostic effect of weight loss prior to chemotherapy was analyzedusing data from 3,047 patients enrolled in 12 chemotherapy protocols of the Eastern Cooperative Oncology Group. The frequency of weight loss ranged from 31 percent for favorable non-Hodgkin's lymphoma to 87 percent in gastric cancer. Median survival was significantly shorter in nine protocols for the patients with weight loss compared to the patients with no weight loss. Chemotherapy response rates were lower in the patients with weight loss, but only in patients with breast cancer was this difference significant. Decreasing weight was correlated with decreasing performance status except for patients with pancreatic and gastric cancer. Within performance status categories, weight loss was associated with decreased median survival. The frequency of weight loss increased with increasing number of anatomic sites involved with metastases, but within categories of anatomic involvement, weight loss was associated with decreased median survival. These observations emphasize the prognostic effect of weight loss, especially in patients with a favorable performance status or a limited anatomic involvement with tumor.

AB - The prognostic effect of weight loss prior to chemotherapy was analyzedusing data from 3,047 patients enrolled in 12 chemotherapy protocols of the Eastern Cooperative Oncology Group. The frequency of weight loss ranged from 31 percent for favorable non-Hodgkin's lymphoma to 87 percent in gastric cancer. Median survival was significantly shorter in nine protocols for the patients with weight loss compared to the patients with no weight loss. Chemotherapy response rates were lower in the patients with weight loss, but only in patients with breast cancer was this difference significant. Decreasing weight was correlated with decreasing performance status except for patients with pancreatic and gastric cancer. Within performance status categories, weight loss was associated with decreased median survival. The frequency of weight loss increased with increasing number of anatomic sites involved with metastases, but within categories of anatomic involvement, weight loss was associated with decreased median survival. These observations emphasize the prognostic effect of weight loss, especially in patients with a favorable performance status or a limited anatomic involvement with tumor.

UR - http://www.scopus.com/inward/record.url?scp=0018949428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018949428&partnerID=8YFLogxK

U2 - 10.1016/S0149-2918(05)80001-3

DO - 10.1016/S0149-2918(05)80001-3

M3 - Article

C2 - 7424938

AN - SCOPUS:0018949428

SN - 0002-9343

VL - 69

SP - 491

EP - 497

JO - American Journal of Medicine

JF - American Journal of Medicine

IS - 4

ER -

Prognostic effect of weight loss prior tochemotherapy in cancer patients

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this